{"entity":{"id":"nct07619521","kind":"trial","name":"Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma","aka":[],"tldr":"A phase 1/2 trial of selumetinib and trastuzumab deruxtecan in pancreatic cancer, run by National Cancer Institute (NCI), now recruiting.","summary":"Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma is a phase 1/2, interventional study registered as NCT07619521 by National Cancer Institute (NCI), with a registry enrolment figure of 31 participants, started 2027-06-01 and due to reach its primary completion in 2028-09-08. Interventions recorded: Biospecimen Collection; Diagnostic Imaging Testing; Echocardiography Test; Multigated Acquisition Scan; Selumetinib; Trastuzumab Deruxtecan. Conditions listed: Advanced Pancreatic Ductal Adenocarcinoma; Metastatic Pancreatic Ductal Adenocarcinoma; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Ductal Adenocarcinoma. Primary outcome: Occurrence of dose limiting toxicities (DLTs) (dose escalation phase); HER2 expression status (dose escalation phase); Overall response rate (phase II). Pancreatic eligibility wording from the registry: \"* Patients must have histologically or cytologically confirmed adenocarcinoma of the pancreas\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07619521","url":"https://clinicaltrials.gov/study/NCT07619521"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["locally-advanced-pdac","metastatic-pdac"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["selumetinib","trastuzumab-deruxtecan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07619521","phase":"1/2","setting":"Phase I/II Study of the MEK Inhibitor Selumetinib Plus DS-8201a (Trastuzumab Deruxtecan) in KRAS-Mutant, HER2-Expressing Pancreatic Ductal Adenocarcinoma","sponsor":"National Cancer Institute (NCI)","enrolled":31,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07619521/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"selumetinib","kind":"drug","name":"Selumetinib","route":"/drugs/selumetinib/"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}